Newbridge Financial Services Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Newbridge Financial Services Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27	Closed	-$113	–	1470
2023 Q1	$113	Hold	27	–	–	﹤0.01%	1358
2022 Q4	$162	Hold	27	–	–	﹤0.01%	1390
2022 Q3	$0	Buy	27 +20	+286%	+$125	﹤0.01%	1530
2022 Q2	$0	Buy	+7	New	+$36	﹤0.01%	1589

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Newbridge Financial Services Group's CTIC Position: Q2 2023 in Review

Newbridge Financial Services Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 27 shares — an estimated $113 sold.

Newbridge Financial Services Group first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $162 in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Newbridge Financial Services Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 27 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $113.
Newbridge Financial Services Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Newbridge Financial Services Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $162 in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Newbridge Financial Services Group's 13F filing for Q2 2023, filed 21 Jul 2023.